Principle Research Solutions
Principle Research Solutions
  • Home
  • Current Studies
  • Mission
  • Services
  • More
    • Home
    • Current Studies
    • Mission
    • Services

  • Home
  • Current Studies
  • Mission
  • Services

Atopic Dermatitis

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, PK, and immunogenicity of multiple subcutaneous doses of TRIV-509 in participants 18 to

75 years of age with moderate to severe AD.

Sign Up/ Request info

Triveni Bio Atopic dermatitis

Participation Information

Volunteers needed for up to a 57-week-long clinical trial with up to 14 office visits for an investigational product. Stipend up to $1980 if eligible. 


To Qualify, you must meet the following INCLUSION CRITERIA:

1.)  18-75 years of age.

2.)  Have moderate to severe eczema (atopic dermatitis).

3.) Must weigh more than 88.2 lbs. 


To Qualify, you  must NOT meet the following EXCLUSION CRITERIA:

1.) History of cancer or lymphoproliferative disease within the last 5 years.

2.)  Test positive for HIV.

3.)  Be pregnant or plan on becoming pregnant. 





 ClinicalTrials.gov ID NCT07167758 

https://clinicaltrials.gov/study/NCT07167758?cond=Atopic%20Dermatitis&term=Triveni&rank=1#study-overview

Contact Us

Drop us a line!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Better yet, see us in person!

We love our patients, so feel free to visit during normal business hours.

Principle Research Solutions,llc

510 S Cowley Spokane, WA 99202

(509) 474-1107 MD@principleresearchsolutions.com

Hours

Mon

09:00 am – 05:00 pm

Tue

09:00 am – 05:00 pm

Wed

09:00 am – 05:00 pm

Thu

09:00 am – 05:00 pm

Fri

09:00 am – 05:00 pm

Sat

Closed

Sun

Closed

Photo Gallery

Copyright © 2025 Principle Research Solutions,llc - All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept